CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

被引：1
|
作者：
Soo, R. A. [1 ]
Cho, B. C. [2 ]
Kim, J-H. [3 ]
Ahn, M-J. [4 ]
Lee, K. H. [5 ,12 ]
Zimina, A. [6 ]
Orlov, S. [7 ]
Bondarenko, I. [8 ]
Lee, Y-G. [9 ]
Ni, L. Yueh [10 ]
Lee, S. S. [11 ]
Lee, K. H. [5 ,12 ]
Pang, Y. K. [13 ]
Fong, C. H. [14 ]
Kang, J. H. [15 ]
Lim, C. S. [16 ]
Danchaivijitr, P. [17 ]
Lee, H. [18 ]
Park, S. [18 ]
Cicin, I. [19 ]
机构：
[1] Natl Univ Canc Inst Singapore, Haematol Oncol Dept, Singapore, Singapore
[2] Yonsei Univ, Yonsei Canc Ctr, Internal Med, Coll Med, Seoul, South Korea
[3] CHA Bundang Med Ctr, Seongnam, South Korea
[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea
[5] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Med, Coll Med, Cheongju, South Korea
[6] State Budgetary Healthcare Inst Omsk Reg, Omsk, Russia
[7] Pavlov State Med Univ, Oncol, St Petersburg, Russia
[8] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine
[9] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Sch Med, Seoul, South Korea
[10] Hosp Umum Sarawak, Sarawak, Malaysia
[11] Inje Univ, Haeundae Paik Hosp, Coll Med, Busan, South Korea
[12] Yeungnam Univ, Dept Internal Med, Med Ctr, Daegu, South Korea
[13] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia
[14] Hosp Pulau Pinang, Dept Radiotherapy & Oncol, Georgetown, Malaysia
[15] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[16] Hosp Sultan Ismail, Oncol Dept, Johor Baharu, Malaysia
[17] Mahidol Univ, Fac Med, Dept Med, Siriraj Hosp, Bangkok, Thailand
[18] Yuhan Corp, Seoul, South Korea
[19] Trakya Univ, Med Oncol Dept, Med Fac, Edirne, Turkiye
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2357
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1324MO
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum plus Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC
    Rybkin, Igor I.
    Smit, Egbert
    Kopp, Hans-Georg
    Kim, Dong-Wan
    Spira, Alexander
    Berruti, Alfredo
    Lee, Dae Ho
    Reguart, Noemi
    Akimov, Mikhail
    Schumacher, Karl
    Upalawanna, Allison
    Squires, Matthew
    Tan, Daniel S. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S307 - S308
  • [42] Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy
    Schuette, W.
    Dietel, M.
    Thomas, M.
    Eberhardt, W.
    Griesinger, F.
    Zirrgiebel, U.
    Radke, S.
    Schirmacher, P.
    PNEUMOLOGIE, 2016, 70 (08): : 514 - 521
  • [43] Amivantamab and lazertinib in treatment-naive EGFR-mutated advanced non-small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
    Lee, Se-Hoon
    Cho, Byoung Chul
    Han, Ji-Youn
    Cho, Eun Kyung
    Lee, Jong-Seok
    Lee, Ki Hyeong
    Curtin, Joshua C.
    Gao, Grace
    Xie, John
    Schnepp, Robert W.
    Bauml, Joshua Michael
    Knoblauch, Roland E.
    Thayu, Meena
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
    Lee, S. -H.
    Cho, B. C.
    Hayashi, H.
    Felip, E.
    Spira, A. I.
    Girard, N.
    Kim, Y. J.
    Ostapenko, Y.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Korbenfeld, E.
    Mourao Dias, J.
    Lee, K. H.
    Xiong, H.
    How, S. H.
    Cheng, Y.
    Chang, G. -C.
    Yang, J. C. -H.
    Besse, B.
    Thomas, M.
    Curtin, J. C.
    Zhang, J.
    Xie, J.
    Sun, T.
    Martinez, M.
    Sethi, S.
    Knoblauch, R. E.
    Fennema, E.
    Daksh, M.
    Ennis, M.
    Bauml, J. M.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S12 - S12
  • [45] Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
    Girard, Nicolas
    Cho, Byoung Chul
    Spira, Alexander I.
    Shu, Catherine A.
    Sanborn, Rachel E.
    Neal, Joel W.
    Marmarelis, Melina Elpi
    Sabari, Joshua K.
    Waqar, Saiama Naheed
    Nagasaka, Misako
    Yang, James Chih-Hsin
    Lu, Shun
    Kambuj, Pritam
    Sanchez, Jeffrey
    Ojeda, Lahila-Carina
    Xie, John
    Mahadevia, Parthiv
    Bauml, Joshua Michael
    Knoblauch, Roland E.
    Hayashi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    LUNG CANCER, 2024, 193
  • [47] Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
    Cho, Byoung Chul
    Han, Ji-Youn
    Lee, Ki Hyeong
    Lee, Yun-Gyoo
    Kim, Dong-Wan
    Min, Young Joo
    Kim, Sang -We
    Cho, Eun Kyung
    Kim, Joo -Hang
    Lee, Gyeong-Won
    Lee, Sung Sook
    Lee, NaMi
    Wang, Jang Young
    Park, Hyejoo
    Ahn, Myung-Ju
    LUNG CANCER, 2024, 190
  • [48] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [50] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
12345